A Phase 3 interventional study of sarilumab SAR153191 (REGN88) and tocilizumab in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 78 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-26.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 3, and was the 10th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2007; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 88 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
36 studies in Arthritis, Rheumatoid by Sanofi: 2 open now, 2 under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 14th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 3, and was the 16th registered.
Sanofi’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 36 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To assess, in the same study, the safety of sarilumab and tocilizumab in participants with rheumatoid arthritis (RA) who were inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.
Total study duration was up to 34 weeks: Screening up to 28 days, treatment phase of 24 weeks, and post-treatment follow-up of 6 weeks.
After completion of the treatment phase of this study, participants were eligible to enter a long term safety study (LTS11210) for active treatment with SAR153191 (REGN88).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of RA was, according to the American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2010 Rheumatoid Arthritis Classification Criteria with ≥ 3 months disease duration
ACR Class I-III functional status, was based on the 1991 revised criteria. Moderate-to-severely active RA. Anti-TNF therapy failures, was defined as participants with an inadequate clinical response was defined by the investigator, after being treated for at least 3 consecutive months, and/or intolerance to at least 1 TNF-antagonist, resulting in or requiring their discontinuation. TNF-antagonists were include, but were not limited to, etanercept, infliximab, adalimumab, golimumab and/or certolizumab pegol
Continuous treatment with one or a combination of non-biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 consecutive weeks prior to screening and on a stable dose(s) for at least 6 consecutive weeks prior to screening:
Exclusion criteria:
Participants \<18 years of age. Use of parenteral or intra-articular corticosteroids within 4 weeks prior to screening
Use of oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day, or a change in dosage within 4 weeks prior to screening
Past history of, or current, or inflammatory systemic or localized joint disease(s) other than RA
History of juvenile idiopathic arthritis or arthritis onset prior to age 16. Severe systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome
Participation in any clinical research study that evaluated an drug or therapy within 5 half-lives or 60 days of the Screening Visit, whichever was longer
Participants with active tuberculosis or latent tuberculosis infection. Prior or current history of interstitial lung disease. Prior treatment with anti-interleukin (IL) -6 or anti-IL-6R therapies, including but not limited to tocilizumab or sarilumab
Treatment with anti-TNF agents, as follows:
Treatment with RA-directed biologic agents with non- TNF-α antagonist mechanisms without adequate as follows:
Prior treatment with a janus kinase (JAK) inhibitor (eg, tofacitinib). Participants with a history of invasive opportunistic infection. Prior or current history of , including lymphoproliferative diseases, other than adequately-treated carcinoma in-situ of the cervix, nonmetastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization (baseline) visit
Prior or current history of other significant concomitant illness(es) that, according to Investigator's judgement, was adversely affect the participant's participation in the study.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) and placebo intravenous (IV) infusion once every 4 weeks (q4w) was added to one or a combination of the nonbiologic disease modifying antirheumatic drug (DMARD), hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
Drug: sarilumab SAR153191 (REGN88) · Drug: hydroxychloroquine · Drug: methotrexate · Drug: sulfasalazine · Drug: leflunomide · Drug: intravenous placebo
Sarilumab 200 mg SC injection q2w and placebo IV infusion q4w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
Drug: sarilumab SAR153191 (REGN88) · Drug: hydroxychloroquine · Drug: methotrexate · Drug: sulfasalazine · Drug: leflunomide · Drug: intravenous placebo
Tocilizumab 4 mg/kg or 8 mg/kg IV infusion q4w and placebo SC injection q2w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
Drug: tocilizumab · Drug: hydroxychloroquine · Drug: methotrexate · Drug: sulfasalazine · Drug: leflunomide · Drug: subcutaneous placebo
Pharmaceutical form: solution Route of administration: subcutaneous
Pharmaceutical form: solution Route of administration: intravenous
Dispensed according to local practice.
Dispensed according to local practice.
Dispensed according to local practice.
Dispensed according to local practice.
Pharmaceutical form: solution Route of administration: subcutaneous
Pharmaceutical form: solution Route of administration: intravenous
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. All adverse events that occurred from the first dose of the study drug administration up to 60 days after the end of treatment visit were considered as TEAEs. Serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. A summary of SAEs, all other non-serious AEs, regardless of causality, are reported in AE section.
Time frame: Up to 211 days
The study was conducted at 78 centers in 19 countries. A total of 389 participants were screened between 25 March 2013 and 02 April 2014, 187 of whom were screen failures. Screen failures were mainly due to failure to meet inclusion and exclusion criteria.
| Milestone | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w |
|---|---|---|---|
| Started | 49 | 51 | 102 |
| Completed | 40 | 39 | 96 |
| Not completed | 9 | 12 | 6 |
| Withdrew: Adverse event | 7 | 8 | 4 |
| Withdrew: Lack of efficacy | 1 | 3 | 1 |
| Withdrew: Other, not due to an adverse event | 1 | 1 | 1 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. All adverse events that occurred from the first dose of the study drug administration up to 60 days after the end of treatment visit were considered as TEAEs. Serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. A summary of SAEs, all other non-serious AEs, regardless of causality, are reported in AE section.
| participants | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w |
|---|---|---|---|
| Any TEAE | 33 | 36 | 68 |
| Any treatment-emergent SAE | 1 | 3 | 7 |
| Any TEAE leading to death | 0 | 0 | 1 |
| Any TEAE leading to discontinuation | 6 | 8 | 4 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 211) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sarilumab 150 mg q2w | — | 1/49 (2%) | 33/49 (67.3%) |
| Sarilumab 200 mg q2w | — | 3/51 (5.9%) | 36/51 (70.6%) |
| Tocilizumab q4w | — | 7/102 (6.9%) | 66/102 (64.7%) |
| Event | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w |
|---|---|---|---|
| Deep vein thrombosisVascular disorders | 1/49 | 0/51 | 0/102 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 1/49 | 0/51 | 0/102 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/49 | 0/51 | 0/102 |
| Urinary tract infectionInfections and infestations | 0/49 | 1/51 | 0/102 |
| Atrial fibrillationCardiac disorders | 0/49 | 1/51 | 0/102 |
| Transaminases increasedInvestigations | 0/49 | 1/51 | 0/102 |
| ErysipelasInfections and infestations | 0/49 | 0/51 | 1/102 |
| Septic shockInfections and infestations | 0/49 | 0/51 | 1/102 |
| NeutropeniaBlood and lymphatic system disorders | 0/49 | 0/51 | 1/102 |
| TremorNervous system disorders | 0/49 | 0/51 | 1/102 |
| Event | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 6/49 | 8/51 | 3/102 |
| NasopharyngitisInfections and infestations | 6/49 | 3/51 | 4/102 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/49 | 3/51 | 9/102 |
| Urinary tract infectionInfections and infestations | 4/49 | 1/51 | 6/102 |
| Injection site erythemaGeneral disorders | 4/49 | 4/51 | 1/102 |
| Upper respiratory tract infectionInfections and infestations | 2/49 | 1/51 | 7/102 |
| NauseaGastrointestinal disorders | 1/49 | 1/51 | 7/102 |
| GastroenteritisInfections and infestations | 3/49 | 0/51 | 1/102 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 2/49 | 1/51 | 6/102 |
| DizzinessNervous system disorders | 1/49 | 3/51 | 4/102 |
| Age, Continuous(years) | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w | Total |
|---|---|---|---|---|
| Mean | 54.8 ± 12.1 | 51.7 ± 13.1 | 50.4 ± 13.0 | 51.8 ± 12.8 |
| Sex: Female, Male(Participants) | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w | Total |
|---|---|---|---|---|
| Female | 41 | 39 | 82 | 162 |
| Male | 8 | 12 | 20 | 40 |
| Duration of rheumatoid arthritis (RA) since diagnosis(years) | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w | Total |
|---|---|---|---|---|
| Mean | 13.59 ± 8.24 | 10.45 ± 7.57 | 10.84 ± 8.91 | 11.41 ± 8.48 |
| RA functional class(participants) | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w | Total |
|---|---|---|---|---|
| I | 10 | 4 | 16 | 30 |
| II | 25 | 33 | 62 | 120 |
| III | 14 | 14 | 24 | 52 |
| IV | 0 | 0 | 0 | 0 |
| Health Assessment Questionnaire Disability Index (HAQ-DI)(units on a scale) | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w | Total |
|---|---|---|---|---|
| Mean | 1.63 ± 0.66 | 1.71 ± 0.60 | 1.78 ± 0.63 | 1.72 ± 0.63 |
| Disease Activity Score for 28 Joints- C-reactive protein (DAS28-CRP)(score on scale) | Sarilumab 150 mg q2w | Sarilumab 200 mg q2w | Tocilizumab q4w | Total |
|---|---|---|---|---|
| Mean | 5.85 ± 0.92 | 5.88 ± 0.97 | 5.91 ± 1.01 | 5.89 ± 0.97 |
The record gives a start of Mar 2013, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 2 years 8 months after primary completion. A results delay was requested in Oct 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab